» Articles » PMID: 35372090

Risk Factors on the Incidence and Prognostic Effects of Colorectal Cancer With Brain Metastasis: A SEER-Based Study

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Apr 4
PMID 35372090
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Colorectal cancer (CRC) with brain metastases (BM) is uncommon and often diagnosed at a late stage. The aims of this study were to identify the clinical factors that can influence the incidence of CRC patients with BM (CRCBM) and to investigate the impact of clinical factors and therapies on the outcomes of CRCBM.

Methods: Between 2010 and 2018, patients with CRCBM were enrolled under the Surveillance, Epidemiology, and End Results (SEER) program. Multivariable logistic and Cox regression models were used to identify risk factors and prognostic factors of BM. Kaplan-Meier curve and log-rank test were used to evaluate overall survival (OS) and tumor-specific survival (CSS) of CRCBM patients.

Results: A total of 195 (0.34%) CRC patients initially diagnosed with BM were included for analysis. The positive level of CEA, pN2a-b, and additional organ metastases were positively associated with developing BM from the CRC cohort ( < 0.05). The median OS and CSS of the BM patients were both 4.0 months, while the corresponding survival time in CRC patients without BM was 14.0 and 16.0 months, respectively (HR = 2.621, 95% CI = 2.061-3.333 for CSS; HR = 2.556, 95% CI = 2.026-3.225 for OS; log rank < 0.001, each). Only systematic treatment was independently associated with better survival ( < 0.05, each).

Conclusions: Although the overall prognosis of CRCBM patients was extremely poor, the positive level of CEA, pN2a-b, and distant metastases could be bad risk factors for the incidence of CRCBM. In addition, only systematic treatment was found to be a negative prognostic factor for CRCBM patients. These related factors can provide more valuable reference for clinical individualized treatments.

Citing Articles

Survival Analysis, Clinical Characteristics, and Predictors of Cerebral Metastases in Patients with Colorectal Cancer.

Jeri-Yabar A, Vittini-Hernandez L, Benites-Meza J, Prado-Nunez S Med Sci (Basel). 2024; 12(3).

PMID: 39311160 PMC: 11417931. DOI: 10.3390/medsci12030047.


Urban vs. rural: colorectal cancer survival and prognostic disparities from 2000 to 2019.

Fu M, Pan S, Cai X, Pan Q Front Public Health. 2024; 12:1319977.

PMID: 38406503 PMC: 10884167. DOI: 10.3389/fpubh.2024.1319977.


Circulating DNA and frequency of colorectal cancer brain metastases in a presumed high-risk group.

Callesen L, Boysen A, Andersen R, Dalby R, Spindler K Sci Rep. 2023; 13(1):18574.

PMID: 37903871 PMC: 10616067. DOI: 10.1038/s41598-023-45939-x.

References
1.
Mege D, Sans A, Ouaissi M, Iannelli A, Sielezneff I . Brain metastases from colorectal cancer: characteristics and management. ANZ J Surg. 2017; 88(3):140-145. DOI: 10.1111/ans.14107. View

2.
Singh Achrol A, Rennert R, Anders C, Soffietti R, Ahluwalia M, Nayak L . Brain metastases. Nat Rev Dis Primers. 2019; 5(1):5. DOI: 10.1038/s41572-018-0055-y. View

3.
Sun J, Wang C, Zhang Y, Xu L, Fang W, Zhu Y . Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases. Nat Commun. 2019; 10(1):3190. PMC: 6639368. DOI: 10.1038/s41467-019-10987-3. View

4.
Damiens K, Ayoub J, Lemieux B, Aubin F, Saliba W, Campeau M . Clinical features and course of brain metastases in colorectal cancer: an experience from a single institution. Curr Oncol. 2012; 19(5):254-8. PMC: 3457876. DOI: 10.3747/co.19.1048. View

5.
Zampino M, Magni E, Ravenda P, Cella C, Bonomo G, Della Vigna P . Treatments for colorectal liver metastases: A new focus on a familiar concept. Crit Rev Oncol Hematol. 2016; 108:154-163. DOI: 10.1016/j.critrevonc.2016.11.005. View